1. Positron emission tomography–computed tomography predictors of progression after DA-R-EPOCH for PMBCL
by Chelsea C. Pinnix, Andrea K. Ng, Bouthaina S. Dabaja, Sarah A. Milgrom, Jillian R. Gunther, C. David Fuller, Grace L. Smith, Zeinab Abou Yehia, Wei Qiao, Christine F. Wogan, Mani Akhtari, Osama Mawlawi, L. Jeffrey Medeiros, Hubert H. Chuang, William Martin-Doyle, Philippe Armand, Ann S. LaCasce, Yasuhiro Oki, Michelle Fanale, Jason Westin, Sattva Neelapu, and Loretta Nastoupil
BloodAdv
Volume 2(11):
June 12, 2018
© 2018 by The American Society of Hematology

2. Chelsea C. Pinnix et al. Blood Adv 2018;2:1334-1343
© 2018 by The American Society of Hematology

3. Survival outcomes after DA-R-EPOCH for PMBCL
Survival outcomes after DA-R-EPOCH for PMBCL. PFS (A) and OS (B) after treatment with DA-R-EPOCH among patients with PMBCL treated at 2 tertiary cancer centers (cohorts 1 and 2).
Survival outcomes after DA-R-EPOCH for PMBCL. PFS (A) and OS (B) after treatment with DA-R-EPOCH among patients with PMBCL treated at 2 tertiary cancer centers (cohorts 1 and 2).
Chelsea C. Pinnix et al. Blood Adv 2018;2:
© 2018 by The American Society of Hematology

4. Effect of pretreatment and posttreatment radiographic parameters on PFS. Elevated pretreatment MTV (A) and TLG (B) were associated with inferior PFS. Posttherapy increased CT residual mass volume (C), SUVmax (D), and end-of-therapy Deauville score (E-F) predicted inferior PFS. The combination of pretreatment TLG and posttreatment Deauville score (G-H) were also associated with decreased PFS.
Effect of pretreatment and posttreatment radiographic parameters on PFS. Elevated pretreatment MTV (A) and TLG (B) were associated with inferior PFS. Posttherapy increased CT residual mass volume (C), SUVmax (D), and end-of-therapy Deauville score (E-F) predicted inferior PFS. The combination of pretreatment TLG and posttreatment Deauville score (G-H) were also associated with decreased PFS.
Chelsea C. Pinnix et al. Blood Adv 2018;2:
© 2018 by The American Society of Hematology